MedTrace Logo

Ultra-rapid Blastocyst Vitrification: Pilot Randomized Study

NCT07556601 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-29

No results posted yet for this study

Summary

Blastocyst vitrification is standard in assisted reproduction, but clinical data on ultra-rapid vitrification are limited. This pilot study evaluates the safety, feasibility, and preliminary clinical performance of an ultra-rapid blastocyst vitrification protocol compared with the standard approach.

Conditions

Interventions

OTHER

Standard Vitrification

1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 10-12 minutes at room temperature. 2. Vitrification solution exposure: Blastocysts are then transferred to Vitrification Solution (VS) for a maximum exposure time of 90 seconds. 3. Loading: The blastocyst is loaded onto a Cryotop device (Kitazato). 4. Vitrification: The Cryotop is plunged directly into liquid nitrogen within 1 second of loading to ensure ultra-rapid cooling. 5. Capping: The Cryotop is immediately capped under liquid nitrogen conditions.

OTHER

Ultra-Rapid Vitrification

The ultra-rapid vitrification protocol is identical to the standard protocol in terms of media, devices, and laboratory conditions, with the following modifications: Preparation step - Blastocyst shrinkage: Prior to equilibration, artificial collapse of the blastocyst is performed using a single laser pulse to induce blastocoel shrinkage. The subsequent steps are: 1. Equilibration step: Blastocysts are equilibrated in Equilibration Solution (ES) for 2-4 minutes. 2. Vitrification solution exposure: Transfer to Vitrification Solution (VS) for a maximum of 90 seconds. 3. Loading: Loading of the blastocyst onto a Cryotop device. 4. Vitrification: Immediate plunging of the Cryotop into liquid nitrogen within 1 second. 5. Capping: Immediate capping under liquid nitrogen.

Sponsors & Collaborators

  • Fundacion Dexeus

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-12-31
Completion
2028-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07556601 on ClinicalTrials.gov